Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase III SANOVO trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in fir | Oct 26, 2026 |
| ESLT | PRESS-RELEASE | neutral | 4/10 | Elbit Systems announced approximately $200 million in contracts from an Asia-Pacific country for airborne ISTAR, trainin | Oct 26, 2026 |
| CTSH | PRESS-RELEASE | neutral | 3/10 | Cognizant announced a five-year strategic partnership with the European Bank for Reconstruction and Development (EBRD) t | Oct 26, 2026 |
| OPNW | PRESS-RELEASE | neutral | 3/10 | OpenWorld confirmed its planned dual listing on Figure OPEN remains on track for Q4 2026, with stockholder approval of t | Oct 25, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase III SAFFRON trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in ME | Oct 25, 2026 |
| ORKA | PRESS-RELEASE | neutral | 6/10 | Oruka Therapeutics will report Week 16 data for its lead candidate ORKA-001 from the EVERLAST-B Phase 2b trial in plaque | Oct 25, 2026 |
| AVBP | PRESS-RELEASE | bullish | 5/10 | ArriVent BioPharma announced encouraging initial Phase 1 results for ARR-217, a CDH17-targeting ADC, in heavily pretreat | Oct 25, 2026 |
| AMRN | PRESS-RELEASE | mixed | 6/10 | Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver metastases | Oct 25, 2026 |
| NBP | PRESS-RELEASE | bullish | 7/10 | NovaBridge presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate and 16.9- | Oct 25, 2026 |
| REGN | PRESS-RELEASE | bullish | 5/10 | Regeneron announced longer-term Phase 3 C-POST data at ESMO 2026 showing adjuvant Libtayo (cemiplimab) in high-risk cuta | Oct 25, 2026 |
| BNTX | PRESS-RELEASE | bullish | 6/10 | BioNTech and BMS reported first Phase 2 data from the ROSETTA Lung-107 trial showing pumitamig plus docetaxel achieved a | Oct 25, 2026 |
| FCAP | PRESS-RELEASE | bullish | 5/10 | First Capital, Inc. reported Q3 2026 net income of $5.1 million ($1.53 per diluted share), up from $4.5 million ($1.34 p | Oct 25, 2026 |
| PBLS | PRESS-RELEASE | bullish | 7/10 | Parabilis Medicines reported updated Phase 1/2 data for zolucatetide in desmoid tumors at ESMO 2026, showing a 72.2% obj | Oct 24, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics announced publication of positive Phase 2/3 COMPANION-002 results for tovecimig in advanced biliary | Oct 24, 2026 |
| CELC | PRESS-RELEASE | bullish | 6/10 | Celcuity presented new subgroup analyses from the Phase 3 VIKTORIA-1 study at ESMO 2026, showing gedatolisib triplet sig | Oct 24, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented updated Phase 1b data for IMA402 PRAME bispecific and Phase 1 data for IMA203CD8 PRAME cell therapy a | Oct 24, 2026 |
| BRCB | PRESS-RELEASE | neutral | 2/10 | Black Rock Coffee Bar announced the opening of a new store in Rancho Cucamonga, California, its eighth location in the s | Oct 23, 2026 |
| HHH | PRESS-RELEASE | bullish | 5/10 | Howard Hughes Holdings Inc. (HHH) will be added to the S&P SmallCap 600 index, replacing Arcosa Inc., effective October | Oct 23, 2026 |
| OXSQ | PRESS-RELEASE | neutral | 1/10 | Oxford Square Capital Corp. announced it will report its Q3 2026 results on October 30, 2026. | Oct 23, 2026 |
| CSV | PRESS-RELEASE | neutral | 1/10 | Carriage Services, Inc. announced it will report its Q3 2026 results. | Oct 23, 2026 |
| ACRE | PRESS-RELEASE | neutral | 1/10 | Ares Commercial Real Estate Corporation announced it will report its Q3 2026 results on November 6, 2026. | Oct 23, 2026 |
| ESOA | PRESS-RELEASE | neutral | 3/10 | Energy Services of America completed the acquisition of FAMCO, a West Virginia water and sewer utility contractor, for a | Oct 23, 2026 |
| GD | PRESS-RELEASE | neutral | 2/10 | General Dynamics appointed Amy Johnson as president of GDIT, effective November 3. Johnson is a 27-year veteran of Gener | Oct 23, 2026 |
| YMAT | PRESS-RELEASE | bearish | 5/10 | J-Star reported H1 2026 revenue of $6.8M, down 36% YoY from $10.6M, driven by an intentional exit from Chinese outsource | Oct 23, 2026 |
| PURR | PRESS-RELEASE | neutral | 3/10 | Hyperliquid Strategies Inc increased its stock repurchase authorization from $30M to $100M and extended the program's te | Oct 23, 2026 |
| MWA | PRESS-RELEASE | neutral | 1/10 | Mueller Water Products Inc announced it will report its Q4 2026 and full-year results. | Oct 23, 2026 |
| ABR | PRESS-RELEASE | neutral | 1/10 | Arbor Realty Trust announced it will host a conference call to discuss its Q3 2026 results. | Oct 23, 2026 |
| SRTA | PRESS-RELEASE | neutral | 1/10 | Strata Critical Medical, Inc announced it will host a conference call to discuss its Q3 2026 results. | Oct 23, 2026 |
| MSEX | PRESS-RELEASE | neutral | 2/10 | Middlesex Water Company announced a 5.56% increase in its quarterly common dividend, marking the 54th consecutive year o | Oct 23, 2026 |
| SUNS | PRESS-RELEASE | bullish | 6/10 | Sunrise Realty Trust stockholders approved the issuance of ~8.46 million shares in connection with its merger with South | Oct 23, 2026 |